Results 21 to 30 of about 4,721 (285)

Machine learning prediction of methionine and tryptophan photooxidation susceptibility

Molecular Therapy: Methods & Clinical Development, 2021
Photooxidation of methionine (Met) and tryptophan (Trp) residues is common and includes major degradation pathways that often pose a serious threat to the success of therapeutic proteins.
Jared A. Delmar, Eugen Buehler, Ashwin K. Chetty, Agastya Das, Guillermo Miro Quesada, Jihong Wang, Xiaoyu Chen   +6 more
doaj   +1 more source

In silico prediction of post-translational modifications in therapeutic antibodies

mAbs, 2022
Monoclonal antibodies are susceptible to chemical and enzymatic modifications during manufacturing, storage, and shipping. Deamidation, isomerization, and oxidation can compromise the potency, efficacy, and safety of therapeutic antibodies.
Shabdita Vatsa
doaj   +1 more source

Characterization and Modeling of Reversible Antibody Self-Association Provide Insights into Behavior, Prediction, and Correction

Antibodies, 2021
Reversible antibody self-association, while having major developability and therapeutic implications, is not fully understood or readily predictable and correctable.
Carl Mieczkowski, Alan Cheng, Thierry Fischmann, Mark Hsieh, Jeanne Baker, Makiko Uchida, Gopalan Raghunathan, Corey Strickland, Laurence Fayadat-Dilman   +8 more
doaj   +1 more source

Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics

mAbs, 2022
Machine learning has been recently used to predict therapeutic antibody aggregation rates and viscosity at high concentrations (150 mg/ml). These works focused on commercially available antibodies, which may have been optimized for stability.
Pin-Kuang Lai, Austin Gallegos, Neil Mody, Hasige A. Sathish, Bernhardt L. Trout   +4 more
doaj   +1 more source

Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties

mAbs, 2023
Antibody drugs should exhibit not only high-binding affinity for their target antigens but also favorable physicochemical drug-like properties. Such drug-like biophysical properties are essential for the successful development of antibody drug products ...
Hristo L. Svilenov, Paolo Arosio, Tim Menzen, Peter Tessier, Pietro Sormanni   +4 more
doaj   +1 more source

An accelerated surface-mediated stress assay of antibody instability for developability studies

mAbs, 2020
High physical stability is required for the development of monoclonal antibodies (mAbs) into successful therapeutic products. Developability assays are used to predict physical stability issues such as high viscosity and poor conformational stability ...
Marie R.G. Kopp, Adriana-Michelle Wolf Pérez, Marta Virginia Zucca, Umberto Capasso Palmiero, Brigitte Friedrichsen, Nikolai Lorenzen, Paolo Arosio   +6 more
doaj   +1 more source

High concentration formulation developability approaches and considerations

mAbs, 2023
The growing need for biologics to be administered subcutaneously and ocularly, coupled with certain indications requiring high doses, has resulted in an increase in drug substance (DS) and drug product (DP) protein concentrations.
Jonathan Zarzar, Tarik Khan, Maniraj Bhagawati, Benjamin Weiche, Jasmin Sydow-Andersen, Alavattam Sreedhara   +5 more
doaj   +1 more source

Nanoscale integration of single cell biologics discovery processes using optofluidic manipulation and monitoring. [PDF]

, 2019
The new and rapid advancement in the complexity of biologics drug discovery has been driven by a deeper understanding of biological systems combined with innovative new therapeutic modalities, paving the way to breakthrough therapies for previously ...
Chen, Ching, Chen, Irwin, Chong, Su, Hamburger, Agi, Jess, Philip, Jorgolli, Marsela, Le, Kim, Lin, Fen-Fen, Miranda, Les P, Mock, Marissa, Munro, Trent, Nevill, Tanner, Stevens, Jennitte, Tagari, Philip, Tan, Christopher, Winters, Aaron, Wu, Ming, Xu, Han   +17 more
core   +1 more source

Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies

mAbs, 2023
To combat the COVID-19 pandemic, potential therapies have been developed and moved into clinical trials at an unprecedented pace. Some of the most promising therapies are neutralizing antibodies against SARS-CoV-2.
Andrew Dippel, Austin Gallegos, Vineela Aleti, Arnita Barnes, Xiaoru Chen, Elizabeth Christian, Jared Delmar, Qun Du, Reza Esfandiary, Erika Farmer, Andrew Garcia, Qing Li, Jia Lin, Weiyi Liu, LeeAnn Machiesky, Neil Mody, Arun Parupudi, Meagan Prophet, Keith Rickert, Kim Rosenthal, Song Ren, Harini Shandilya, Reena Varkey, Kevin Wons, Yuling Wu, Yueh-Ming Loo, Mark T. Esser, Nicole L. Kallewaard, Sarav Rajan, Melissa Damschroder, Weichen Xu, Gilad Kaplan   +31 more
doaj   +1 more source

Developed-developing country partnerships: Benefits to developed countries? [PDF]

Globalization and Health, 2012
Abstract Developing countries can generate effective solutions for today’s global health challenges. This paper reviews relevant literature to construct the case for international cooperation, and in particular, developed-developing country partnerships.
Syed, Shamsuzzoha B, Dadwal, Viva, Rutter, Paul, Storr, Julie, Hightower, Joyce D, Gooden, Rachel, Carlet, Jean, Bagheri Nejad, Sepideh, Kelley, Edward T, Donaldson, Liam, Pittet, Didier   +10 more
openaire   +4 more sources